GlassScriptPhysician profile
Ami J Patel
NPI 1568656593
$6,309.35
in general payments reported to CMS, 2019-2025
27 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $925 · 2022: $1,255 · 2023: $1,095 · 2024: $1,828 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,966 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,965.77 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $1,273.32 | 2022-2025 | Aplenzin |
| Astellas Pharma US INC | $897.46 | 2021-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $745.20 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $728.00 | 2021-2025 | |
| Amgen INC. | $374.76 | 2021-2025 | Evenity, Prolia, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $328.15 | 2021-2025 | Trintellix |
| Pfizer INC. | $326.64 | 2023-2025 | |
| Therapeuticsmd, INC. | $283.46 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $191.96 | 2021 | |
| Eisai INC. | $134.89 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $131.91 | 2022 | |
| Myovant Sciences INC. | $131.23 | 2021-2022 | |
| Lundbeck LLC | $125.32 | 2024-2025 | Rexulti |
| Coopersurgical, INC. | $92.68 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Alfasigma USA, INC. | $88.53 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.46 | 2022-2023 | Belsomra, Lagevrio |
| Idorsia Pharmaceuticals US INC | $58.87 | 2022-2024 | Quviviq |
| Ascend Therapeutics US, LLC | $49.58 | 2022 | |
| Dermavant Sciences, INC. | $47.66 | 2024 | Vtama |
| Sumitomo Pharma America, INC. | $42.80 | 2023 | Myfembree |
| Lilly USA, LLC | $38.11 | 2021 | |
| Boston Scientific Corporation | $37.75 | 2022 | |
| Avanos Medical | $35.53 | 2025 | On-Q Pump and Accessories |
| Exact Sciences Corporation | $25.40 | 2025 | |
| Novo Nordisk INC | $22.93 | 2023 | Wegovy |
| Avion Pharmaceuticals | $18.33 | 2022 | |
| Organon LLC | $12.42 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.